Literature DB >> 9455908

Hypoglycosylation of a brain glycoprotein (beta-trace protein) in CDG syndromes due to phosphomannomutase deficiency and N-acetylglucosaminyl-transferase II deficiency.

S Pohl1, A Hoffmann, A Rüdiger, M Nimtz, J Jaeken, H S Conradt.   

Abstract

Human beta-trace protein is a major intrathecally synthesized polypeptide constituent of human cerebrospinal fluid. We have previously shown that this protein is almost quantitatively modified with biantennary complex-type N-linked oligosaccharides which show "brain-type" glycosylation characteristics (Hoffmann,A. et al., J. Neurochem., 63, pp. 2185-2191, 1994). In the present study human beta-trace protein from the cerebrospinal fluid (CSF) of patients with carbohydrate-deficient glycoprotein syndrome (CDGS) due to phosphomannomutase (PMM) deficiency and N-acetyl-glucosaminyltransferase II (GlcNAc-T II) deficiency as well as from control individuals was studied by Western blot analysis. The protein from pooled CSFs was purified by immunoaffinity chromatography. The protein from the five patients with CDGS PMM deficiency showed three protein bands upon SDS-PAGE analysis corresponding to the di-, mono-, and unglycosylated polypeptide forms. Carbohydrate structural analysis of the enzymatically liberated N-glycans was performed applying mapping by HPAEC-PAD, methylation analysis as well as MALD/TOF-MS. Essentially identical oligosaccharide structures were detected in beta-TP from type I patients and control adult pooled CSF. The beta-trace protein from two patients with GlcNAc-T II deficiency showed a single di-N-glycosylated protein band with a significantly lower molecular weight than the di-glycosylated polypeptide from control patients and the beta-trace protein from pooled adult CSF. Beta-TP from GlcNAc-T II deficiency patients shared only three oligosaccharides out of the 13 observed in beta-TP from controls or patients with PMM deficiency. The major oligosaccharide structures of the glycoprotein from patients with GlcNAc-T II deficiency were found to be monoantennary asialo- or monosialylated lactosamine-type chains with proximal fucose and bisecting GlcNAc.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9455908     DOI: 10.1093/glycob/7.8.1077

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  9 in total

Review 1.  Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells.

Authors:  E Grabenhorst; P Schlenke; S Pohl; M Nimtz; H S Conradt
Journal:  Glycoconj J       Date:  1999-02       Impact factor: 2.916

2.  The sugar moiety of Tamm-Horsfall protein is affected by the carbohydrate-deficient glycoprotein type I syndrome. A case study.

Authors:  T Olczak; M Olczak; A Kubicz
Journal:  Glycoconj J       Date:  1999-09       Impact factor: 2.916

3.  Changes in concanavalin A-reactive proteins in neurological disorders.

Authors:  L Saso; G Valentini; M G Leone; E Grippa; R Guglielmi; L Paris; G Cantore; B Silvestrini
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

Review 4.  The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation.

Authors:  Luisa Sturiale; Rita Barone; Domenico Garozzo
Journal:  J Inherit Metab Dis       Date:  2011-03-08       Impact factor: 4.982

5.  The normal phenotype of Pmm1-deficient mice suggests that Pmm1 is not essential for normal mouse development.

Authors:  K Cromphout; W Vleugels; L Heykants; E Schollen; L Keldermans; R Sciot; R D'Hooge; P P De Deyn; K von Figura; D Hartmann; C Körner; G Matthijs
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

6.  L-PGDS (betatrace protein) inhibits astrocyte proliferation and mitochondrial ATP production in vitro.

Authors:  Xiaorong Xin; Andreas Huber; Peter Meyer; Josef Flammer; Albert Neutzner; Neil R Miller; Hanspeter E Killer
Journal:  J Mol Neurosci       Date:  2009-07-14       Impact factor: 3.444

Review 7.  Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.

Authors:  Kavitha Siva; Giuseppina Covello; Michela A Denti
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

Review 8.  Primary immunodeficiency diseases associated with neurologic manifestations.

Authors:  Soodabeh Fazeli Dehkordy; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2011-10-26       Impact factor: 8.542

Review 9.  CDG Therapies: From Bench to Bedside.

Authors:  Sandra Brasil; Carlota Pascoal; Rita Francisco; Dorinda Marques-da-Silva; Giuseppina Andreotti; Paula A Videira; Eva Morava; Jaak Jaeken; Vanessa Dos Reis Ferreira
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.